key: cord-0945118-33d323wx authors: Lat, Tasnim I.; Patel, Chhaya D.; Ehrig, Jessica C.; Moslander, Conner; Sanchez, Juan F. title: Therapeutic Options in the Treatment of SARS-CoV-2 in the Pregnant Patient date: 2020-09-12 journal: Am J Obstet Gynecol MFM DOI: 10.1016/j.ajogmf.2020.100224 sha: 77e88fe4acce75f837dc71e7870fd03f046f34a1 doc_id: 945118 cord_uid: 33d323wx The SARS-CoV-2 pandemic has resulted in the development of various therapeutics to treat and prevent major complications related to the virus; pregnant patients are vulnerable to acquiring SARS-CoV-2 due to frequent contact with the healthcare setting. Despite publication of a plethora of case series and randomized control trials of SARS- CoV-2 therapeutics, few have addressed treatment in the pregnant population. To date, there have been no published review of therapeutics in the pregnant patient infected with SARS-CoV-2. We provide the first review of available treatments for SARS-CoV-2, various trials with inclusion and exclusion of the pregnant patients, and potential side effects of each treatment in the pregnant patient. Overall, the findings were promising; however, the study was subject to limitations 214 based on lack of randomized design. Furthermore, the vast majority of patients were 215 male and no enrolled patients were pregnant, so little could be extrapolated to the 216 pregnant population from this study. 16 Recently, two randomized control trials 217 regarding use of Remdesivir in the treatment of SARS-CoV-2 have been published. 218 The first was a randomized, double-blind, placebo-controlled trial by Wang the treatment group compared with the control group. Of note, this benefit was not 295 found in the critically ill patients (i.e. those requiring mechanical ventilation or in 296 multiforgan failure). There were no statistically significant differences between the 297 convalescent plasma group vs the control group in any of the major secondary 298 outcomes, including 28-day mortality (15.7% vs 24.0%, respectively; P = .30). The 299 study was underpowered due to being terminated early as the outbreak in Wuhan 300 was near controlled so definitive conclusions about efficacy could not be 301 established. Finally, pregnant patients were excluded from this study. The trend 302 towards improvement in patients who were severely ill but not critically ill suggests 303 administration early in the course of disease process rather than later in the disease 304 process may benefit patients. 22 Broad-spectrum antiviral GS-5734 500 inhibits both epidemic and zoonotic coronaviruses Remdesivir and chloroquine effectively inhibit 503 the recently emerged novel coronavirus (2019-nCoV) in vitro Compassionate Use of Remdesivir for 506 Patients with Severe Covid-19 Remdesivir in adults with severe COVID-19: a 509 randomised, double-blind, placebo-controlled, multicentre trial Remdesivir for the Treatment of 512 The effectiveness of 516 convalescent plasma and hyperimmune immunoglobulin for the treatment of 517 severe acute respiratory infections of viral etiology: a systematic review and 518 exploratory meta-analysis Treatment of 5 Critically Ill Patients With 521 COVID-19 With Convalescent Plasma Deployment of convalescent plasma 524 for the prevention and treatment of COVID-19 Effect of Convalescent Plasma Therapy on Time to 527 Clinical Improvement in Patients With Severe and Life-threatening COVID-528 19: A Randomized Clinical Trial Convalescent plasma for coronavirus disease 2019 532 in pregnancy: A case report and review. Retrieved Expanded Access to 536 Convalescent Plasma for the Treatment of Patients with COVID-19 Identifier NCT04343755. Convalescent Plasma as 541 Treatment for Patients Hospitalized with COVID-19 Infection The pathogenesis and treatment of the `Cytokine Storm' 545 in COVID-19 Effective treatment of severe COVID-19 patients with 547 tocilizumab Potential therapeutic agents against COVID-19: 550 What we know so far Clinical evidence does not support 554 corticosteroid treatment for 2019-nCoV lung injury Dexamethasone in 561 Hospitalized Patients with Covid-19 -Preliminary Report Pulmonary Embolism and Increased 565 Levels of d-Dimer in Patients with Coronavirus Disease Coagulopathy and Antiphospholipid 569 Antibodies in Patients with Covid-19 ISTH interim guidance on recognition and 572 management of coagulopathy in COVID-19 Anticoagulant treatment is 575 associated with decreased mortality in severe coronavirus disease 2019 576 patients with coagulopathy Coronavirus disease 2019 in pregnancy: consider 579 thromboembolic disorders and thromboprophylaxis ISIDOG Recommendations 583 Concerning COVID-19 and Pregnancy Antirheumatic medications in pregnancy and 586 breastfeeding Tocilizumab use in pregnancy: 589 Analysis of a global safety database including data from clinical trials and 590 The use of corticosteroids in the treatment of SARS-CoV-2 is conjectured to mitigate 357 the widespread inflammatory response that results in multiorgan failure. During the 358 early months of the pandemic, corticosteroid use in SARS-CoV-2 was linked to 359 increased morbidity and mortality in patients, conjectured due to decreased 360 clearance of viral RNA from the blood and the respiratory tract. 29 In pregnancy, 361 corticosteroids are commonly given for fetal lung maturity in the event of 362 premature delivery (between 23 and 36 weeks of gestation); however, dosing for 363 fetal lung maturity is only a fraction of the dosing that was reportedly used in 364 patients infected with SARS-CoV-2. 30